清胰利胆颗粒联合埃索美拉唑对老年急性胰腺炎患者炎性介质和肠黏膜屏障功能的影响

Effects of Qingyi Lidan Granule combined with esomeprazole on inflammatory mediators and intestinal mucosal barrier function in elderly patients with acute pancreatitis

摘要:

目的 探讨清胰利胆颗粒联合埃索美拉唑对老年急性胰腺炎患者炎性介质和肠黏膜屏障功能的影响。方法 选取2018年1月—2019年12月永康市第一人民医院收治的老年急性胰腺炎患者60例，采用随机数字表法分为观察组和对照组，每组30例。观察组给予清胰利胆颗粒联合埃索美拉唑治疗，对照组给予埃索美拉唑治疗。两组疗程均7 d。比较两组腹痛和腹胀缓解时间；治疗前与治疗7 d炎性介质［白细胞介素-6（IL-6）、超敏C反应蛋白（hs-CRP）、肿瘤坏死因子-α（TNF-α）］和肠黏膜屏障功能［二胺氧化酶（DAO）、内毒素和D-乳酸］的变化。结果 观察组腹痛和腹胀缓解时间均短于对照组（P <0.05）。观察组治疗前后IL-6、hs-CRP、TNF-α的差值大于对照组（P <0.05）。观察组治疗前后DAO、内毒素、D-乳酸的差值大于对照组（P <0.05）。结论 清胰利胆颗粒联合埃索美拉唑可减轻老年急性胰腺炎患者炎症反应，改善患者肠黏膜屏障功能。

Abstract:

Objective To investigate the effects of Qingyi Lidan Granule combined with esomeprazole on inflammatory mediators and intestinal mucosal barrier function in elderly patients with acute pancreatitis (AP).Methods The 60 elderly patients with AP admitted to Yongkang First People's Hospital from January 2018 to December 2019 were randomly divided into two groups, with 30 cases in each group. The observation group was given Qingyi Lidan Granule combined with esomeprazole, while the control group was given only esomeprazole. The course of treatment was 7 days. The relief time of abdominal pain and distension, and changes in inflammatory mediators [interleukin-6 (IL-6), high-sensitivity C-reactive protein (hs-CRP) and tumor necrosis factor-α (TNF-α)] and intestinal mucosal barrier function as assessed via diamine oxidase (DAO), endotoxin and D-lactic acid before and 7 days after treatment, were compared between the two groups.Results The relief time of abdominal pain and distension in the observation group was shorter than that in control group (P < 0.05). The differences of IL-6, hs-CRP and TNF-α before and after treatment in the observation group were higher than those in control group (P < 0.05). The difference of DAO, endotoxin and D-lactic acid before and after treatment in the observation group were higher than those in control group (P < 0.05).Conclusions Qingyi Lidan Granule combined with esomeprazole can reduce the inflammatory reaction and improve the intestinal mucosal barrier function in AP patients.